Catalyst Wire Dossier Catalyst Wire Dossier

13-valent Pneumococcal Conjugate Vaccine (PCV13i)

pneumococcal conjugate vaccine, 13-valent · CanSino Biologics Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 13-valent Pneumococcal Conjugate Vaccine (PCV13i), covering 2026-02-27 to 2026-02-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) [Phase 3]

See pricing